This article is more than 5 years old. Information may no longer be current.

Seven updates in pancreatic cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

With over 9,000 newly-diagnosed patients each year, pancreatic cancer is the only major cancer with a 5-year survival rate below 10%, at only 8%, according to Pancreatic Cancer Action Network.

In conjunction with Pancreatic Cancer Awareness Month and 2016 World Pancreatic Cancer Day, HemOnc Today presents seven updates in pancreatic cancer screening, diagnosis and treatment.

• Patients with pancreatic cancer who initiated chemotherapy more than 12 weeks following resection appeared to experience similar survival as patients who initiated chemotherapy earlier. Read more.
• Plasma 25-hydroxyvitamin D levels of 30 ng/mL or higher appeared associated with longer pancreatic cancer survival, according to an analysis of five U.S. prospective cohort studies. Read more.
• Screening adults with new-onset diabetes for pancreatic cancer may be effective for early diagnosis and treatment initiation. Read more.
• The addition of capecitabine to standard adjuvant gemcitabine chemotherapy significantly extended survival of patients with resected pancreatic ductal adenocarcinoma. Read more.
• Rucaparib (Clovis Oncology) showed clinical efficacy in a small cohort of patients with pancreatic cancer and BRCA mutations. Read more.
• The addition of radiation to chemotherapy failed to improve OS for patients with locally advanced pancreatic cancer, according to the results of the randomized, open-label, phase 3 LAP07 trial. Read more.
• Online health information regarding pancreatic cancer often overestimated the reading level of the general population and lacked accurate information about alternative therapeutic options, according to study results published in JAMA Surgery. Read more.